Trial Profile

A Phase 1 Dose-escalation Study of PSMA ADC in Subjects With Progressive, Castration-resistant, Metastatic Prostate Cancer.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Dec 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PSMA ADC (Primary)
Indications Prostate cancer
Focus Adverse reactions; First in man
Sponsors Progenics Pharmaceuticals

Most Recent Events

01 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
14 Feb 2013 Updated results were presented at the 2013 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium according to a Progenics Pharmaceutical media release. Results were also briefly summarised in the media release.
28 Sep 2012 Results will be presented at the 2012 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics according to a Progenics Pharmaceuticals media release. Results were also briefly summarised in the media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com